Repligen Corporation (NASDAQ:RGEN) Reports Record Sales In 2Q; The CEO Walter C. Herlihy Passed Positive Remarks

Boston, MA 08/12/2014 (wallstreetpr) – On August 11, 2014, Repligen Corporation (NASDAQ:RGEN), the life-science company announced its second quarter’s financial result that ended on June 30, 2014. Product revenue: The product revenue of Repligen Corporation (NASDAQ:RGEN) in the 2Q rose 19.5% over the last year’s comparable quarter to $15.6 million. In the product revenue for this […]

Repligen Corporation (NASDAQ:RGEN) Delivers Strong 2Q Sales Of Protein A Affinity Ligands

Boston, MA 08/11/2014 (wallstreetpr) – Life science company Repligen Corporation (NASDAQ:RGEN) delivered strong sales and earnings number for the second quarter driven by robust sales of protein A affinity ligands apart from higher demand for its chromatography products. As a result, the company’s bottom line came in more than the Street analysts’ estimations. CEO Comments […]

Repligen Corporation (NASDAQ:RGEN) Taps Life Technologies (LIFE) Executive

Boston, MA 05/13/2014 (wallstreetpr) – Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and commercializes products used in the manufacturing of biological drugs. The company announced the hiring of Tony J. Hunt, a former executive at Life Technologies Corp (NASDAQ:LIFE). The company announced that Mr. Hunt will fill the Chief Operating Offering position […]